logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
L

Li-Yuan Bai

China Medical University Hospital
H指数:26
被引数:4,156

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Diterpene, Ent-9α,11α-dihydroxy-15-oxo-kaur-16-En-19-oic Acid From the Herbal Plant Adenostemma lavenia, Induces Apoptosis and Autophagy in Oral Squamous Cell Carcinoma Cells

从草药植物<i>Adenostemma lavenia</i>中分离得到的一种二萜类化合物<i>Ent</i>-9<i>α</i>,11<i>α</i>-二羟基-15-氧代-柯巴-16-烯-19-羧酸，可诱导口腔鳞状细胞癌细胞的凋亡和自噬

Journal of Food Biochemistry
IF4.2
2026-09-020
OAAI
Kun-Chang Wu; Li-Yuan Bai; Po-Chen Chu; Jing-Lan Hu; Jing-Ru Weng
Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial

新型口服抗血管生成拟态药物CVM-1118在晚期分化良好的神经内分泌肿瘤中的疗效与安全性：一项IIa期临床试验

British Journal of Cancer
IF6.8
2026-07-020
OA
Chia-Jui Yen; Ming-Huang Chen; Yen-Yang Chen; Li-Yuan Bai; Jen-Shi Chen; Jason Chia-Hsun Hsieh; Yu-Hsuan Shih; I-Chen Wu; Yen-Ling Chen; Chun-Man Chen; Ting-Yu Chao; Yi-Wen Chu; Du-Shieng Chien
Response to comment on “Considering the unmeasured impact of 5-fluorouracil dose intensity in the interpretation of optimal initial relative dose intensity of modified FOLFIRINOX”

对“在解释改良FOLFIRINOX最佳初始相对剂量强度时考虑5-氟尿嘧啶剂量强度的未测量影响”的评论回复

Journal of the Formosan Medical Association
IF2.5
2026-05-220
OAAI
I-Wei Ho; Chung-Pin Li; Shih-Hung Yang; Hsiu-Tzu Wang; Ching-Yeh Lin; Yung-Yeh Su; Ching-Liang Ho; Wen-Chi Chou; Tai-Jan Chiu; Yu-Hsuan Shih; Yin-Hsun Feng; Yueh-Shih Chang; Chao-Chien Hung; Chang-Fang Chiu; Li-Yuan Bai
Response to Comment on “Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort”

对“改良FOLFIRINOX在胰管腺癌中的最佳初始相对剂量强度：一项回顾性多中心队列研究”的评论回复

Journal of the Formosan Medical Association
IF2.5
2026-05-050
OAAI
I-Wei Ho; Chung-Pin Li; Shih-Hung Yang; Hsiu-Tzu Wang; Ching-Yeh Lin; Yung-Yeh Su; Ching-Liang Ho; Wen-Chi Chou; Tai-Jan Chiu; Yu-Hsuan Shih; Yin-Hsun Feng; Yueh-Shih Chang; Chao-Chien Hung; Chang-Fang Chiu; Li-Yuan Bai
Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort

改良FOLFIRINOX在胰管腺癌中的最佳初始相对剂量强度：一项回顾性多中心队列研究

Journal of the Formosan Medical Association
IF2.5
2026-04-120
OAAI
I-Wei Ho; Chung-Pin Li; Shih-Hung Yang; Hsiu-Tzu Wang; Ching-Yeh Lin; Yung-Yeh Su; Ching-Liang Ho; Wen-Chi Chou; Tai-Jan Chiu; Yu-Hsuan Shih; Yin-Hsun Feng; Yueh-Shih Chang; Chao-Chien Hung; Chang-Fang Chiu; Li-Yuan Bai
Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine–nab-paclitaxel failure: a propensity score-matched analysis

二线5-FU联合纳米脂质体伊立替康与FOLFOX/XELOX方案对比：在吉西他滨–白蛋白结合型紫杉醇治疗失败后的转移性胰腺癌中的倾向性评分匹配分析

ESMO Open
IF8.3
2025-11-070
OAAI
G. Trovato; D. Rossini; A. Guidolin; Y.-Y. Su; Y.-S. Shan; N.-J. Chiang; W.-C. Chou; L.-Y. Bai; C. Bagalà; M. Bensi; M. Niger; S. Marchesi; S.K. Garattini; A. Michelotti; A. Pretta; M. Scartozzi; C. Vivaldi; L. Bartalini; L. Procaccio; F. Bergamo; L. Antonuzzo; L.-T. Chen; L. Salvatore; G. Tortora
Nanoliposomal Irinotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Head and Neck and Esophageal Squamous Cell Carcinoma After Prior Platinum-Based Chemotherapy or Chemoradiotherapy: A Multicenter Phase II Trial

纳米脂质体伊立替康联合5-氟尿嘧啶和亚叶酸钙用于经前期铂类为基础的化疗或放化疗后的晚期头颈及食管鳞状细胞癌：一项多中心II期临床试验

Cancer Medicine
IF3.1
2025-10-210
OAAI
Muh-Hwa Yang; Shang-Yin Wu; I-Wei Ho; Nai-Jung Chiang; Chin-Fu Hsaio; Chen-Yuan Lin; Ming-Yu Lien; Peter Mu-Hsin Chang; Jia-Hong Chen; Ching-Yun Hsieh; Ruey-Long Hong; Chao-Tung Lee; Li-Tzong Chen; Tsang-Wu Liu; Chang-Fang Chiu; Li-Yuan Bai
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer (vol 9, 103647, 2024)
ESMO OPEN
IF8.3
2025-01-010
OAAI
Chen, L. -T.; Vogel, A.; Hsu, C.; Chen, M. -H.; Fang, W.; Pangarsa, E. A.; Sharma, A.; Ikeda, M.; Park, J. O.; Tan, C. K.; Regala, E.; Tai, D.; Tanasanvimon, S.; Charoentum, C.; Chee, C. E.; Lui, A.; Sow, J.; Oh, D. -Y.; Ueno, M.; Ramaswamy, A.; Jeo, W. S.; Zhou, J.; Curigliano, G.; Yoshino, T.; Bai, L. -Y.; Pentheroudakis, G.; Chiang, N. -J.; Cervantes, A.; Chen, J. -S.; Ducreux, M.
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial

Nivolumab联合化疗治疗HER2-negative，既往未治疗，不可切除，晚期或复发性胃/胃食管交界癌患者: 吸引-4随机，双盲，安慰剂对照，3期临床试验的3年随访

GASTRIC CANCER
IF5.1
2024-08-201
OAAI
Boku, Narikazu; Omori, Takeshi; Shitara, Kohei; Sakuramoto, Shinichi; Yamaguchi, Kensei; Kato, Ken; Kadowaki, Shigenori; Tsuji, Kunihiro; Ryu, Min-Hee; Oh, Do-Youn; Oh, Sang Cheul; Rha, Sun Young; Lee, Keun-Wook; Chung, Ik-Joo; Sym, Sun Jin; Chen, Li-Tzong; Chen, Jen-Shi; Bai, Li-Yuan; Nakada, Takashi; Hagihara, Shunsuke; Makino, Reina; Nishiyama, Eiji; Kang, Yoon-Koo
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer

泛亚适应ESMO临床实践指南，用于胆道癌患者的诊断，治疗和随访

ESMO OPEN
IF8.3
2024-08-010
OAAI
Chen, L. -T; Vogel, A.; Hsu, C.; Chen, M. -h.; Fang, W.; Pangarsa, E. A.; Sharma, A.; Ikeda, M.; Park, J. O.; Tan, C. K.; Regala, E.; Tai, D.; Tanasanvimon, S.; Charoentum, C.; Chee, C. E.; Lui, A.; Sow, J.; Oh, D. -y.; Ueno, M.; Ramaswamy, A.; Jeo, W. S.; Zhou, J.; Curigliano, G.; Yoshino, T.; Bai, L. -y.; Pentheroudakis, G.; Chiang, N. -j.; Cervantes, A.; Chen, J. -s.; Ducreux, M.

研究方向

暂未获取到该数据
L
Li‐Tzong Chen
H 指数:55论文数:538被引数:1.7万
N
Nai‐Jung Chiang
H 指数:22论文数:150被引数:1,503
C
Chang‐Fang Chiu
H 指数:22论文数:129被引数:2,918
Y
Yan‐Shen Shan
H 指数:41论文数:374被引数:7,552
J
Jen‐Shi Chen
H 指数:44论文数:307被引数:2.4万
D
Do‐Youn Oh
H 指数:81论文数:950被引数:4.3万
Y
Yung‐Yeh Su
H 指数:13论文数:70被引数:424
C
Chung‐Pin Li
H 指数:42论文数:209被引数:8,044
W
Wen‐Chi Chou
H 指数:32论文数:323被引数:4,408
C
Chia‐Jui Yen
H 指数:36论文数:360被引数:1.2万